Edition:
India

Zoetis Inc (ZTS.N)

ZTS.N on New York Stock Exchange

82.79USD
23 Feb 2018
Change (% chg)

$2.03 (+2.51%)
Prev Close
$80.76
Open
$81.17
Day's High
$82.93
Day's Low
$81.04
Volume
596,669
Avg. Vol
701,244
52-wk High
$82.93
52-wk Low
$52.25

Chart for

About

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock)... (more)

Overall

Beta: 1.03
Market Cap(Mil.): $31,180.87
Shares Outstanding(Mil.): 489.11
Dividend: 0.10
Yield (%): 0.66

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.91 10.66
ROE: -- 16.41 14.30

BRIEF-Zoetis Inc Q4 Earnings Per Share $0.16

* ADJUSTED NET INCOME FOR 2017 ‍EXCLUDES ONE-TIME PROVISIONAL NET TAX CHARGE OF $212 MILLION RELATED TO RECENTLY ENACTED TAX LEGISLATION IN U.S. ​

15 Feb 2018

BRIEF-Zoetis Says Preliminarily Estimated Reduction To Gaap Net Income In Q4

* ZOETIS SAYS EVALUATING IMPACT OF U.S. TAX ACT, PRELIMINARILY ESTIMATED REDUCTION TO GAAP NET INCOME IN Q4 Source text: (http://bit.ly/2qDYvyf) Further company coverage:

08 Jan 2018

BRIEF-Zoetis Launches Vanguard CIV H3N2/H3N8 Vaccine For Canine Influenza Virus

* ZOETIS LAUNCHES VANGUARD CIV H3N2/H3N8 VACCINE FOR CANINE INFLUENZA VIRUS Source text for Eikon: Further company coverage:

12 Dec 2017

BRIEF-Zoetis Board Approves 20% Dividend Increase

* ZOETIS DECLARES FIRST QUARTER 2018 DIVIDEND; BOARD APPROVES 20% PAYMENT INCREASE

12 Dec 2017

BRIEF-Zoetis Inc Q3 earnings per share $0.61

* Q3 earnings per share view $0.62 -- Thomson Reuters I/B/E/S

02 Nov 2017

BRIEF-Zoetis announces pricing of $1.25 bln of senior notes

* Zoetis Inc - ‍agreed to sell $1.25 billion of senior notes, consisting of $750 million aggregate principal amount of 3.000% senior notes due 2027​

06 Sep 2017

BRIEF-Immunovaccine announces achievement of milestones in collaboration with Zoetis to develop veterinary vaccines

* Immunovaccine announces achievement of milestones in collaboration with Zoetis to develop veterinary vaccines Source text for Eikon: Further company coverage:

31 Aug 2017

Competitors

  Price Chg
Merck & Co., Inc. (MRK.N) $54.87 +0.30
Bayer AG (BAYGn.DE) €97.92 -0.52
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €65.05 +0.16
Eli Lilly and Co (LLY.N) $78.75 +1.56

Earnings vs. Estimates